CD274 and head and neck squamous cell carcinoma: A recent phase III, multicenter trial assessed the treatment outcomes of unresected locally advanced HNSCC with the addition of the PD-L1 inhibitor, avelumab, to standard cisplatin-based chemoradiotherapy versus chemoradiotherapy alone [44].